Characterization of Vemurafenib Phototoxicity in a Mouse Model

Toxicological Sciences

Volumn 137, Issue 1, 2014, Pages 259-267

  Boudon, Stéphanie Marie ^a   Plappert Helbig, Ulla ^a   Odermatt, Alex ^b   Bauer, Daniel ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Braf; Llna; Photosafety; Photosensitivity; Phototoxicity; Vemurafenib

Indexed keywords

VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTOTOXICITY; RADIATION EXPOSURE; TREATMENT DURATION; ULTRAVIOLET RADIATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DERMATITIS, PHOTOTOXIC; DOSE RESPONSE; DRUG EFFECTS; LOCAL LYMPH NODE ASSAY; MAXIMUM TOLERATED DOSE; METABOLISM; PATHOLOGY; RADIATION RESPONSE; SKIN; TIME; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DERMATITIS, PHOTOTOXIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ERYTHEMA; FEMALE; INDOLES; LOCAL LYMPH NODE ASSAY; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN; SULFONAMIDES; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 84891317922     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft237     Document Type: Article

References (16)

1. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
2. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al.; BRIM-3 Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
3. Committee for Medicinal Products for Human Use (CHMP) (2011). Assessment Report of Zelboraf, vemurafenib. EMA/CHMP/926998/2011
4. Dummer, R., Rinderknecht, J., and Goldinger, S. M. (2012). Ultraviolet A and photosensitivity during vemurafenib therapy. N. Engl. J. Med. 366, 480-481.
5. FDA/Center for Drug Evaluation and Research, Division of Drug Oncology Products (HFD-150) (2011). Pharmacology and Toxicology NDA Review and Evaluation of Zelboraf, vemurafenib.
6. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
7. Ferguson, J. (2002). Photosensitivity due to drugs. Photodermatol. Photoimmunol. Photomed. 18, 262-269.
8. Gelot, P., Dutartre, H., Khammari, A., Boisrobert, A., Schmitt, C., Deybach, J. C., Nguyen, J. M., Seité, S., and Dréno, B. (2013). Vemurafenib: An unusual UVA-induced photosensitivity. Exp. Dermatol. 22, 297-298.
9. Glantz, S. A. (1992). Primer of Biostatistics, 3rd ed. McGraw-Hill, New York, NY.
10. ICH. (2013). Harmonized Tripartite Guidline S10 "Photosafety evaluation of pharmaceuticals", 2013, http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html accessed online at November 01, 2013.
11. Lacouture, M. E., Duvic, M., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013). Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18, 314-322.
12. Mackay, J. M., and Elliott, B. M. (1992). Dose-ranging and dose-setting for in vivo genetic toxicology studies. Mutat. Res. 271, 97-99.
13. OECD (2004). Test No. 432: In Vitro 3T3 NRU Phototoxicity Test, OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing Paris, France.
14. Shah, N., Iyer, R. M., Mair, H. J., Choi, D. S., Tian, H., Diodone, R., Fähnrich, K., Pabst-Ravot, A., Tang, K., Scheubel, E., et al. (2013). Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J. Pharm. Sci. 102, 967-981.
15. Ulrich, P., Streich, J., and Suter, W. (2001). Intralaboratory validation of alternative endpoints in the murine local lymph node assay for the identification of contact allergic potential: Primary ear skin irritation and ear-draining lymph node hyperplasia induced by topical chemicals. Arch. Toxicol. 74, 733-744.
16. Vohr, H. W., Blümel, J., Blotz, A., Homey, B., and Ahr, H. J. (2000). An intralaboratory validation of the Integrated Model for the Differentiation of Skin Reactions (IMDS): Discrimination between (photo)allergic and (photo)irritant skin reactions in mice. Arch. Toxicol. 73, 501-509.